Comparing blood clotting in sickle cell disease types SS and SC
Part of Blood & lymphatic, Genetic & congenital, Heart & circulation clinical trials.
This study looks at how blood clots and platelets behave in people with the two most common types of sickle cell disease (SS and SC). It aims to understand differences that may help manage the disease better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have sickle cell disease (type SS or SC).
- You are 18 years old or older.
- You are feeling steady at the moment — no sickle cell crisis in the last month.
- You have not had a blood transfusion in the last three months.
- You are followed at one of the two participating sickle cell centers in Guadeloupe or Bobigny (France).
- You are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how severe dengue fever affects people with sickle cell disease. It aims to understand why some people with sickle cell get very sick from dengue and how their cells react.
This study looks at whether regular red blood cell exchange (a treatment that replaces sickled red blood cells with healthy ones) can reduce blood clotting and inflammation in people with sickle cell disease. It aims to see if this treatment helps protect your blood vessels.
This trial tests a “biochip” device using samples from people with sickle cell disease. If it works, it may help doctors study sickle cell biology more accurately using patient samples.
This study collects blood samples to learn more about sickle cell-related genetics and biology. You might benefit indirectly by helping researchers understand the condition, even though this is laboratory research rather than a medication trial.
This trial tests an investigational drug called DISC-3405 in people with sickle cell disease (SCD) to see if it is safe and how it affects your body. It may be an option if you have certain SCD complications or lab results.
This study collects feedback through surveys, interviews, and focus groups from people affected by sickle cell disease. Your input helps the research team improve how genomic and gene-therapy information and needs are understood for patients and caregivers.
Hear when a new Sickle Cell Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.